基于CT的Node-RADS评估可切除胰腺导管腺癌区域淋巴结转移及术后复发
单中心回顾性研究纳入216例直接手术的PDAC患者，以病理为参考标准评估术前CT Node-RADS的诊断效能。Node-RADS≥3在患者、淋巴结组和站水平均显示良好敏感度和特异度，AUC分别为0.815、0.791和0.814，并独立预测更短的无复发生存时间（SHR 1.68，95%CI 1.19-2.36，p=0.003）。
要点
- Node-RADS≥3诊断区域淋巴结转移在患者水平敏感度77.3%、特异度83.9%。
- Node-RADS≥3独立预测术后复发，SHR 1.68（95%CI 1.19-2.36）。
- 可辅助术前识别淋巴结转移风险，支持新辅助治疗决策。
核心结论
- 术前CT Node-RADS≥3可有效评估PDAC区域淋巴结转移并独立预测术后复发。
研究设计与样本
- 单中心回顾性研究纳入2017年1月至2023年7月接受增强CT和手术切除的216例PDAC患者，平均年龄66.6±9.1岁，男性122例。
- 以病理为参考标准，对每个切除淋巴结站独立分配Node-RADS评分。
诊断标准与关键数值
- 以Node-RADS≥3为 cutoff，患者水平诊断淋巴结转移敏感度77.3%（119/154）、特异度83.9%（52/62），AUC 0.815。
- 组1（group 1）敏感度74.8%（104/139）、特异度81.8%（63/77），AUC 0.791。
- 组2（group 2）敏感度77.3%（34/44）、特异度82.6%（142/172），AUC 0.814。
- 逐站分析敏感度60.0%~84.6%，特异度79.1%~97.7%。
- 多因素Fine-Gray分析显示Node-RADS≥3独立预测更短复发时间（SHR 1.68，95%CI 1.19-2.36，p=0.003）。
临床应用与阅片要点
- 术前阅片时可应用Node-RADS评分评估区域淋巴结，评分≥3提示转移风险高。
- Node-RADS≥3与术后复发风险增加相关，可辅助个体化手术规划和新辅助治疗决策。
局限性
- 单中心回顾性研究设计。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
英文原文（摘要）· 点击展开
OBJECTIVES: To evaluate the diagnostic performance of preoperative CT-based Node-RADS for regional lymph node (LN) metastasis and its prognostic value for postoperative recurrence in pancreatic ductal adenocarcinoma (PDAC).
MATERIALS AND METHODS: This single-center retrospective study included patients with PDAC undergoing contrast-enhanced CT and surgical resection between January 2017 and July 2023. Node-RADS scores were independently assigned for each resected LN station, with histopathology as the reference standard. Diagnostic performance was evaluated at the patient, LN group, and station levels using sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC). Fine-Gray analysis was performed to assess the prognostic association of Node-RADS on time to recurrence (TTR) after adjustment for clinicopathologic variables.
RESULTS: A total of 216 patients (mean age, 66.6 ± 9.1 years; 122 men) were included, with LN metastases in 154 (71.3%). Using a cutoff of Node-RADS ≥ 3, the sensitivity and specificity for detecting LN metastasis were 77.3% (119 of 154) and 83.9% (52 of 62) at the patient level, 74.8% (104 of 139) and 81.8% (63 of 77) for group 1, and 77.3% (34 of 44) and 82.6% (142 of 172) for group 2, with AUCs corresponding of 0.815, 0.791, and 0.814. Per-station analysis showed sensitivity ranging from 60.0% to 84.6% and specificity from 79.1% to 97.7%. Multivariable Fine-Gray analyses confirmed that Node-RADS ≥ 3 independently predicted shorter TTR (subdistribution hazard ratio, 1.68; 95% CI: 1.19-2.36; p = 0.003).
CONCLUSION: Preoperative CT-based Node-RADS enabled promising assessment of regional LN metastasis and prediction of postoperative recurrence in PDAC.
KEY POINTS: Question Accurate preoperative identification of regional LN metastasis in PDAC remains challenging, limiting prognosis assessment and individualized treatment allocation. Findings Node-RADS ≥ 3 on preoperative CT demonstrates robust diagnostic performance across patient, group, and station levels and independently predicts shorter recurrence-free survival in PDAC. Clinical relevance CT-based Node-RADS provides promising preoperative assessment of regional nodal involvement and recurrence prediction in PDAC, facilitating personalized surgical planning and decision-making regarding neoadjuvant therapy.
引用
- Chen FM, Li Y, Xu J, et al. CT-based Node-RADS for evaluating regional lymph node metastasis and postoperative recurrence in patients with pancreatic ductal adenocarcinoma undergoing upfront surgery. Eur Radiol. 2026. PMID: 42120755. doi:10.1007/s00330-026-12564-x
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。